CTSO Cytosorbents Corp

Price (delayed)

$0.922

Market cap

$50.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$57.2M

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the ...

Highlights
The gross profit rose by 19% year-on-year and by 5% since the previous quarter
CTSO's EPS is up by 17% YoY and by 8% from the previous quarter
The quick ratio has shrunk by 50% YoY and by 15% QoQ
The equity has declined by 35% year-on-year and by 19% since the previous quarter

Key stats

What are the main financial stats of CTSO
Market
Shares outstanding
54.31M
Market cap
$50.07M
Enterprise value
$57.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.64
Price to sales (P/S)
1.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.56
Earnings
Revenue
$36.69M
EBIT
-$28.25M
EBITDA
-$26.1M
Free cash flow
-$23.45M
Per share
EPS
-$0.59
Free cash flow per share
-$0.43
Book value per share
$0.35
Revenue per share
$0.68
TBVPS
$0.87
Balance sheet
Total assets
$47.07M
Total liabilities
$28.14M
Debt
$17.22M
Equity
$18.93M
Working capital
$6.57M
Liquidity
Debt to equity
0.91
Current ratio
1.49
Quick ratio
1.26
Net debt/EBITDA
-0.27
Margins
EBITDA margin
-71.1%
Gross margin
64.1%
Net margin
-75.1%
Operating margin
-76.8%
Efficiency
Return on assets
-55%
Return on equity
-129.9%
Return on invested capital
-66.3%
Return on capital employed
-84%
Return on sales
-77%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-5.92%
1 week
11.08%
1 month
15.25%
1 year
-72.31%
YTD
-16.94%
QTD
-2.95%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$36.69M
Gross profit
$23.51M
Operating income
-$28.18M
Net income
-$27.54M
Gross margin
64.1%
Net margin
-75.1%
The gross profit rose by 19% year-on-year and by 5% since the previous quarter
The net margin has increased by 15% year-on-year and by 4.2% since the previous quarter
The gross margin is up by 15% YoY and by 4.1% QoQ
Cytosorbents's operating margin has increased by 14% YoY and by 11% QoQ

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
2.64
P/S
1.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.56
CTSO's EPS is up by 17% YoY and by 8% from the previous quarter
CTSO's P/B is 65% lower than its 5-year quarterly average of 8.1 and 30% lower than its last 4 quarters average of 4.0
The equity has declined by 35% year-on-year and by 19% since the previous quarter
The stock's price to sales (P/S) is 74% less than its 5-year quarterly average of 5.5 and 37% less than its last 4 quarters average of 2.3
Cytosorbents's revenue has increased by 3.5% YoY

Efficiency

How efficient is Cytosorbents business performance
The ROE has plunged by 57% YoY and by 8% from the previous quarter
CTSO's ROS is up by 16% YoY and by 4% from the previous quarter
The ROA has decreased by 12% YoY
The ROIC has grown by 10% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The company's total assets is 67% higher than its total liabilities
The quick ratio has shrunk by 50% YoY and by 15% QoQ
CTSO's current ratio is down by 45% year-on-year and by 16% since the previous quarter
The debt is 9% smaller than the equity
The debt to equity is up by 47% year-on-year and by 18% since the previous quarter
The equity has declined by 35% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.